Syros Pharmaceuticals, Inc. - common stock (SYRS) News
Filter SYRS News Items
SYRS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SYRS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest SYRS News From Around the Web
Below are the latest news stories about SYROS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SYRS as an investment opportunity.
South Africa’s Westfalia Fruit acquires Belgian avocado products maker SyrosSyros supplies products under its professional market brand Syros and consumer market brand Wonky. |
Kia launches Syros compact SUV in IndiaAutomaker claims it sets new standards in its segment. |
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary GoalSYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study. |
Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. WainwrightH.C. Wainwright downgraded Syros Pharmaceuticals (SYRS) to Neutral from Buy with a price target of $1, down from $6, after the company announced that the Phase 3 SELECTMDS-1 trial, which evaluated tamibarotene combined with azacitidine for newly diagnosed, higher-risk myelodysplastic syndrome patients with RARA gene overexpression, did not achieve its primary endpoint. The firm removed tamibarotene from its valuation and downgraded the shares. Published first on TheFly – the ultimate source for |
Syros stock craters after lead cancer therapy flops in Phase III trialThe company plans to discontinue the study after the combination therapy failed to meet the primary endpoint in the Phase III trial. |
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene OverexpressionCAMBRIDGE, Mass., November 12, 2024--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the SELECT-MDS-1 Phase 3 trial evaluating tamibarotene in combination with azacitidine in newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression did not meet its primary endpoint of complete response (CR) rate. Tamibarotene is Sy |
Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023)Syros Pharmaceuticals ( NASDAQ:SYRS ) Third Quarter 2024 Results Key Financial Results Net loss: US$6.40m (loss... |
Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ...Despite a revenue drop, Syros Pharmaceuticals Inc (SYRS) advances its promising pipeline with a pivotal trial and financial stability. |
Syros Reports Third Quarter 2024 Financial Results and Provides a Business UpdateCAMBRIDGE, Mass., October 31, 2024--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2024 and provided a business update. |
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024CAMBRIDGE, Mass., October 24, 2024--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, October 31, 2024 to report its third quarter 2024 financial results and provide a business update. |